Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Vactosertib |
Synonyms | |
Therapy Description |
Vactosertib (TEW 7197) is a small molecule that inhibits ALK5, leading to decreased TGF-beta signaling and potentially resulting in decreased tumor cell metastasis (PMID: 24817629, PMID: 31673825) |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Vactosertib | EW-7197|TEW-7197|TEW 7197 | TGFB inhibitor 5 | Vactosertib (TEW 7197) is a small molecule that inhibits ALK5, leading to decreased TGF-beta signaling and potentially resulting in decreased tumor cell metastasis (PMID: 24817629, PMID: 31673825) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05588648 | Phase Ib/II | Vactosertib | Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma | Recruiting | USA | 1 |
NCT03074006 | Phase Ib/II | Vactosertib | Dose Escalation and Proof-of-Concept Studies of TEW-7197 Monotherapy in Patients With Myelodysplastic Syndrome (MDS) | Completed | USA | 0 |
NCT02160106 | Phase I | Vactosertib | First in Human Dose Escalation Study of TEW-7197 in Subjects With Advanced Stage Solid Tumors | Completed | USA | 0 |
NCT04103645 | Phase II | Vactosertib | Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients | Terminated | USA | 0 |